Marshall Wace
WINT

Marshall Wace’s Windtree Therapeutics Inc WINT Stock Holding History

Marshall Wace’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-9,180
Closed -$229K – 1155
2014
Q2 		$229K Buy
+9,180
New +$235K ﹤0.01% 823

Other funds holding WINT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return

Marshall Wace's WINT Position: Q3 2014 in Review

Marshall Wace sold out of Windtree Therapeutics Inc (WINT) in Q3 2014, closing a stake of 9,180 shares — an estimated $229K sold.

Marshall Wace first reported a position in WINT in Q2 2014 and held it in 1 quarter. The position peaked at $229K in Q2 2014. 62 funds tracked by Wall St. Rank hold WINT as of Q3 2014.

  • Marshall Wace reported no remaining Windtree Therapeutics Inc position as of Q3 2014 after selling out during the quarter.
  • Marshall Wace sold 9,180 Windtree Therapeutics Inc shares in Q3 2014, an estimated $229K.
  • Marshall Wace first reported a position in Windtree Therapeutics Inc in Q2 2014 and held it in 1 quarter.
  • Marshall Wace's Windtree Therapeutics Inc position peaked at $229K in Q2 2014.
  • 62 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q3 2014.

Based on Marshall Wace's 13F filing for Q3 2014, filed 13 Nov 2014.